Esomeprazole is used to treat conditions where there is too much acid in the stomach.
The Pharmacy and Poisons Board (PPB) on Tuesday, August 20 announced the recall of S-PRAZO (Esomeprazole Magnesium Delayed-Release Capsules 40mg) Batch No SPZ-302 which is manufactured by Laborate Pharmaceutical India Limited.
Esomeprazole is used to treat conditions where there is too much acid in the stomach.
Furthermore, it is used to treat duodenal and gastric ulcers, erosive esophagitis, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome, a condition wherein the stomach produces too much acid.
Popular ulcers drug S-Prazo (Esomeparazoole Magnesium Delayed-Release Capsules 40mg) Batch No SPZ-302 recalled by the government. /PHARMACY AND POISONS BOARD
In a statement, PPB revealed that it recalled the medicinal product after complaints of a mix-up of blister strips, and some boxes were found to contain two different strips.
“The Pharmacy and Poisons Board (“the Board”) wishes to inform the public of the voluntary recall of S-PRAZO (Esomeprazole Magnesium Delayed-Release Capsules 40mg) Batch No SPZ-302 Manufactured by Laborate Pharmaceutical India Limited,” stated PPB in part.
“The product batch is being recalled following a market complaint regarding a mix-up of blister strips; some boxes were found to contain two different blister strips, i.e. S-Prazo Capsules and Donystatin Tablets, within the same outer carton.”
The Board therefore advised all pharmaceutical outlets, healthcare facilities, healthcare professionals and members of the public to stop further distribution, sale, issuing or use of the product batch.
Once done, Kenyans were advised to return the specified product batch to their nearest healthcare facility or respective suppliers.
While making the announcement, the pharmacy and poisons board assured Kenyans of its commitment to protect the public against sub-standard drugs.
Members of the public were similarly urged to promptly report cases of substandard drugs or adverse drug reactions.
“The reports may be made to the nearest healthcare facility or the Pharmacy and Poisons,” the pharmacy and poisons board directed Kenyans.
In July this year, PPB warned Kenyans against the purchase and use of Ozempic Pens (Semaglutide) to treat type 1 and type 2 diabetes.
On July 18, PPB stated that it had received an alert from the International Criminal Police Organization (INTERPOL) regarding the falsification of Ozempic Pens (Semaglutide) where Apidra Solostar pens (glulisine) used to treat both type 1 and type 2 diabetes had been falsely relabelled as Ozempic (Semaglutide) Pens.
The board consequently informed the public that Ozempic Pens are currently not registered or authorized by the Board to be placed in the Kenyan market.
A photo of the inside of a pharmacy. /FILE